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Background: Acute kidney injury (AKI) is a common clinical problem. Studies have documented the incidence of
AKI in a variety of populations but to date we do not believe the real incidence of AKI has been accurately
documented in a district general hospital setting.
The aim here was to describe the detected incidence of AKI in a typical general hospital setting in an unselected
population, and describe associated short and long-term outcomes.
Methods: A retrospective observational database study from secondary care in East Kent (adult catchment
population of 582,300). All adult patients (18 years or over) admitted between 1st February 2009 and 31st July 2009,
were included. Patients receiving chronic renal replacement therapy (RRT), maternity and day case admissions were
excluded. AKI was defined by the acute kidney injury network (AKIN) criteria. A time dependent risk analysis with
logistic regression and Cox regression was used for the analysis of in-hospital mortality and survival.
Results: The incidence of AKI in the 6 month period was 15,325 pmp/yr (adults) (69% AKIN1, 18% AKIN2 and 13%
AKIN3). In-hospital mortality, length of stay and ITU utilisation all increased with severity of AKI. Patients with AKI
had an increase in care on discharge and an increase in hospital readmission within 30 days.
Conclusions: This data comes closer to the real incidence and outcomes of AKI managed in-hospital than any
study published in the literature to date. Fifteen percent of all admissions sustained an episode of AKI with
increased subsequent short and long term morbidity and mortality, even in those with AKIN1. This confers
an increased burden and cost to the healthcare economy, which can now be quantified. These results will
furnish a baseline for quality improvement projects aimed at early identification, improved management, and
where possible prevention, of AKI.
Keywords: AKI, Incidence, Impact, Outcomes, General hospitalBackground
Acute kidney injury (AKI) is a common clinical problem
characterised by an abrupt decline in kidney function,
ranging from a small rise in serum creatinine (SCr) to
anuric kidney failure requiring renal replacement ther-
apy (RRT). AKI may either be present on admission to
hospital, or develop during the course of admission. The
many aetiologies and risk factors for AKI are well de-
scribed [1-4], as are the short and long term conse-
quences [1,2,4-7].
In the last decade the definition of AKI has been stan-
dardised, refined and adopted in clinical research [6,8]
leading to improved understanding of the epidemiology* Correspondence: Michael.bedford@nhs.net
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unless otherwise stated.of AKI and a realisation of its potential health econom-
ics impact [9].
A number of studies have documented the incidence
of AKI in a variety of populations [9-20] but to date we
do not believe that the real incidence of AKI has been
accurately documented in a district general hospital set-
ting. The aims of this study were therefore to (i) use the
acute kidney injury network (AKIN) definition to de-
scribe the real incidence of AKI in a typical general hos-
pital setting in an unselected patient population, (ii)
describe the associated short and long-term outcomes,
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University NHS Foundation Trust (EKHUFT) between 1st
February and 31st July 2009 were included. Time of entry
to the cohort was the date of admission for each patient.
EKHUFT comprises 3 general hospitals with a total of
1250 inpatients beds serving a defined population of ap-
proximately 744,400 people (582,300 adults) in the geo-
graphical area of East Kent in the southeast peninsula of
England [21]. Patients were followed up until the 31st
March 2011. Patients receiving chronic renal replacement
therapy (RRT) (including dialysis and renal transplant-
ation), maternity admissions and day case admissions were
excluded from the analyses.
Data extraction
Data were extracted from the EKHUFT data warehouse.
This data warehouse stores patient demographics and all
patient episodes, including primary diagnosis and co-
morbidity for each episode. Unique patient identifiers
were used to link the data warehouse with the pathology
database.
AKI was defined by the AKIN criteria using the lowest
SCr in the 12 months prior to the date of hospital admis-
sion as the reference after the method of Lafrance et al.
[22]. In cases where there were no pre-hospitalisation
values and the follow up SCr (lowest in the 12 months fol-
lowing discharge) was lower than the peak in the study
admission, the follow up creatinine was used as the refer-
ence SCr. The assumption was made that if SCr had
improved following admission by greater than 26.4 μmol/L,
then the admission must have involved an AKI (UK
Renal Association, Acute Kidney Injury Clinical Practice
Guideline) [23].
The peak creatinine during the inpatient stay was used
to define the stage of AKI.
Independent variables
Patient demographics (to determine age and eGFR cal-
culations), postcode (to determine deprivation score),
co-morbidity, and primary diagnosis were extracted.
Both co-morbidity and primary diagnosis were coded for
each hospital episode on the data warehouse using ICD-
10 codes. For primary diagnoses the ICD-10 group was
extracted for each admission (Additional file 1: Table S1).
For co-morbidity (secondary diagnoses), validated coding
algorithms from Quan et al., [24] with further validated al-
gorithms for diabetes [25] and hypertension, were used to
determine a modified Charlson co-morbidity score for
each patient. The number of admissions and outpatient
appointments in the 12 months prior to a patient admis-
sion were also recorded. From the baseline pathology data,
the baseline chronic kidney disease (CKD) stage was de-
fined for each patient, using the baseline creatinine (lowest
creatinine in the 12 months prior to admission), or thepost-discharge nadir creatinine was used for the subset of
patients without a pre-hospitalisation creatinine.Outcomes
Mortality, hospital length of stay (LOS), intensive care
LOS, and change in residence resulting from admission
were recorded. Date of death and 30 day re-admission
rates were also recorded wherever relevant. The date of
death was obtained from the Patient Master Index (PMI)
on the hospital patient administration system (PAS).
Where a patient died in hospital this field was populated
using the discharge details of the patient’s episode and
was therefore validated at the point the patient was dis-
charged as ‘died in hospital’. Where a patient died fol-
lowing discharge the PAS PMI record was updated via a
weekly report from the Open Exeter national system
which provides the date of death for any patient recently
deceased [26]. Data on LOS, intensive care LOS, re-
admission, and place of discharge were complete, as re-
corded on the hospital PAS.
All admissions during the recruitment and follow up
periods were extracted. AKI stage was calculated for all
admissions until the end of the follow up in order to in-
form the survival analysis.
Data were also extracted from the renal data system
(Renal Plus, CHI) and from the intensive care database
to determine whether patients in this cohort received RRT
during admission, and whether they were still dependent
on RRT 90 days post discharge. Patients who received
RRT (often in ITU) but did not meet the creatinine cri-
teria for AKIN 3, were upgraded to AKIN 3 in line with
the specifications of the AKIN criteria.Statistical methods
Patient level demographic summaries were performed,
considering a single observation per patient. For patients
with more than one admission with AKI data were sum-
marised at the time of the admission with their highest
AKI stage where there was a valid reference SCr. For pa-
tients who had no valid AKI recordings over the course
of the study, data from the first admission was used in
the analysis.
Normally distributed data were summarised as the mean
and standard deviation. Continuous data not normally dis-
tributed were summarised by median and inter-quartile
range, or the percentage of values in each category for cat-
egorical variables.
Three of the continuous variables, Charlson co-morbidity
score, number of previous admissions in the previous
12 months, and number of outpatient appointments in the
previous 12 months all had a very highly skewed distribu-
tion. So that outlying values were not overly influential,
these three variables were categorised for analysis.
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tensive therapy unit (ITU) utilisation, and increase in
care following discharge. Regression analyses were per-
formed to determine the impact of AKI on each outcome.
Variables used in the regression model, and thought to be
confounders were age, gender, primary diagnosis, modified
Charlson co-morbidity score, stage of chronic kidney dis-
ease (CKD). We also added admission from residential or
nursing care, deprivation index, hospital admissions and
outpatient appointments in the last 12 months. The ana-
lyses were performed in three stages. In the first analysis,
the effect of AKI upon each outcome was examined (an
unadjusted analysis). The second analysis was age and
gender adjusted and the third analysis was multiply ad-
justed, including the above variables.
For primary diagnosis in the regression model, specif-
ically for elective admissions there were diagnosis groups
with too few events. Therefore elective admissions were
set as the reference and emergency admissions split by
ICD-10 group for primary diagnosis.
Logistic regression was used for the analysis of in-
hospital mortality and Cox regression for survival ana-
lysis. A time dependent risk analysis for survival was
employed to allow adjustment for multiple admissions
during the study and follow up period.
Analysis of LOS, which was highly skewed, was per-
formed using negative binomial regression. The ana-
lysis of LOS was performed at the admission level in
the recruitment period, and hence patients may have
contributed to the analysis several times during the
recruitment period. To allow for the correlation between
repeat LOS values from the same patients a multilevel
approach was employed, equivalent to fitting a random-Figure 1 Derivation of the study population.effects model for subjects in addition to the fixed effects
model.
In order to assess the social impact of AKI the change
in residence related to the admission was assessed. An
increase in care from home prior to admission to hos-
pital, to residential or nursing care on discharge, was
classified as an increase in care on discharge. This as-
sessment was performed by stage of AKI.
Results
Population characteristics and AKI
During the 6 month recruitment period there were
66,829 admissions in 45,621 adult patients (Figure 1).
After exclusion of maternity and day case admissions
there were 36,015 admissions in 27,436 patients (79.1%
of patients had 1 admission during the 6 month recruit-
ment, 14.6% had 2 admissions, 4.1% had 3 and 2.2% had
4 or more). Overall, there were 10,030 admissions in
7,496 patients with insufficient SCr data to define AKI.
Of these 42.9% were elective admissions and 57.1% were
non-elective, the majority had a LOS of 0–2 days (see
below). There were 20,464 admissions with no AKI and
5,521 admissions with AKI (8.8% of all admissions and
15.3% of non-maternity and non-day case admissions).
Of these, 3,961 admissions had AKIN 1, 927 admissions
AKIN 2, and 633 admissions AKIN 3. Of the 5,521 ad-
missions with AKI, 4064 had AKI on admission (73.6%)
and 531 of 633 admissions with AKIN 3 (83.9%) had
AKI on admission.
Of the 36,015 admissions, baseline creatinine data in the
12 months prior to admission was available in 31,435
(87%). In the remaining 4,580 admissions the lowest cre-
atinine in the 12 months following discharge (in survivors)
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admissions, 7.2% had AKIN 1, 1.4% AKIN 2 and 1.3%
AKIN 3. This is in comparison to admissions in which a
baseline from the 12 months following discharge was not
used, in which 11.5% had AKIN 1, 2.7% AKIN 2 and 1.8%
AKIN 3. In admissions culminating in mortality baseline
creatinine data was obtainable in 1209/1379 (88%).
Overall, only 455/5521 admissions with AKI (8.2%) in-
volved the calculation of a baseline using the lowest cre-
atinine in the 12 months following discharge.
For descriptive statistics patients without sufficient
SCr data (“no AKI info”) are reported in the results but
only those patients with valid SCr data sufficient to de-
fine AKI were included in the regression analyses. Pa-
tients with insufficient data to define AKI were younger,
had less co-morbidity and shorter LOS than other pa-
tients (Tables 1 and 2).
The crude incidence of AKI in the 6 month period was
3,067 patients with AKIN 1, 807 AKIN 2, and 588 AKIN
3. In total, 4,462 patients from a catchment population of
approximately 582,300 adults experienced AKI during the
6 month recruitment period, assuming the same incidence
for the remaining 6 months of the year from a population
of 582,300 this represents an incidence of 15,325 per mil-
lion (adult) population per year (pmp/yr).
Co-morbidity as evidenced by the Charlson co-morbidity
score was over represented in patients with AKI, and in-
creased with AKI stage (Table 1). Deprivation was not re-
lated to AKI stage.
Renal Replacement Therapy (RRT)
Only 77 patients of the 588 patients with AKIN 3 (13.1%)
received RRT. Of these, 16 remained on RRT 90 days fol-
lowing discharge (2.7% of AKIN 3). A further 4 patients
who experienced AKIN 3 in their index admission (admis-
sion with highest AKI stage during the recruitment
period) who did not require RRT during that admission,
subsequently required chronic RRT within 90 days of dis-
charge. There were also 2 patients with AKIN 1, 2 patients
with AKIN 2 and 1 patient with no AKI info who did not
require RRT in the index admission but subsequently re-
quired chronic RRT within 90 days of discharge. In total
25 patients were on chronic RRT at 90 days.
Survival analyses
Throughout follow up survival was related to AKI stage,
(Table 3, Figure 2). In the upgraded risk analysis, after
12 months 92% of patients who had no AKI were still
alive, in comparison to 28% of patients who experienced
AKIN 3 (Figure 2).
Increasing severity of AKI was associated with increased
risk of death and shorter survival even after multiple ad-
justment, AKIN 1 almost doubling the risk of death and
AKIN 2 and 3 increasing the risk of death almost 3.8-foldand 5.5-fold respectively compared to those with no AKI
(Table 4).
In-hospital mortality
Overall, 1,379 (3.8%) of 36,015 hospital admissions in the
recruitment period resulted in an in-hospital mortality.
Only 2.0% of patients without AKI died in hospital com-
pared with 8.1%, 25.6% and 33.3% of patients with AKIN
1, 2 and 3 respectively. AKI severity was significantly asso-
ciated with in-hospital mortality even after multiple ad-
justment, the likelihood of mortality increasing 2.4 fold
with AKIN 1 and 12 and 26 fold with AKIN 2 and 3 re-
spectively compared to patients with no AKI (Table 4).
Length of stay
In those patients who died in hospital LOS prior to death
averaged 10.0-13.5 days irrespective of AKI (Table 2). In
those surviving to leave hospital LOS was associated with
severity of AKI, ranging from a mean LOS of 4.4 days in
patients without AKI, to 17.2 days in patients with AKIN
3. Compared to those with no AKI after multiple adjust-
ment LOS was 1.5, 1.9 and 2.2-fold greater in those with
AKIN 1, AKIN 2 and AKIN 3 respectively (Table 4).
Intensive Therapy Unit (ITU) utilisation
ITU utilisation increased with increasing AKI severity;
3.9%, 6.8% and 21.6% of patients with AKIN 1, 2 and 3 re-
spectively were admitted to ITU, compared with 1.8% of
patients without AKI. Intensive care LOS also increased
with severity of AKI from a mean of 3.0 (SD 7.0) days in
patients without AKI, to 4.4 (SD 7.8), 4.5 (5.4) and 7.3 (8.0)
days in patients with AKIN stage 1, 2 and 3 respectively.
After multiple adjustment, AKI severity was again associ-
ated with ITU utilisation. Patients were 2.8, 6 and 22
fold more likely to be transferred to ITU with AKIN
stage 1, 2 and 3 respectively compared to patients without
AKI. In patients who went to ITU their length of stay in
ITU was 37%, 35%, and 111% longer in patients with
AKIN stage 1,2 and 3 respectively compared to patients
without AKI.
Increase in care
A greater proportion of patients with AKI (4.5% AKIN 1,
5.7% AKIN 2 and 3.7% AKIN 3) had an increase in care on
discharge in comparison to patients without AKI (1.9%).
Although having an episode of AKI conferred a greater risk
of increase in level of care post-discharge there was no as-
sociation with severity of AKI (Table 4).
Hospital readmission
Having an episode of AKI was also associated with an
increase in hospital readmission within 30 days com-
pared with those without AKI (Table 4), although this
did not associate with severity of AKI.
Table 1 Summaries of mean age, gender, deprivation and co-morbidity at a patient level, only considering admissions
during the recruitment period, and for multiple admissions per patient during the recruitment period selecting the
patient’s admission with the highest AKI stage
Variable No AKI AKIN 1 AKIN 2 AKIN 3 No AKI info
(n = 15,478) (n = 3,067) (n = 807) (n = 588) (n = 7,496)
Age - Mean (SD) 62.0 (20.3) 74.2 (16.3) 76.1 (14.7) 72.5 (15.7) 54.2 (21.0)
Age: 18-39 17.1% 5.1% 3.6% 4.4% 29.0%
40-59 23.7% 11.3% 8.9% 16.0% 28.3%
60-79 36.9% 38.2% 37.3% 40.7% 29.5%
80+ 22.3% 45.5% 50.2% 39.0% 13.2%
Male Sex - % 45.1% 52.2% 45.0% 49.8% 45.8%
Deprivation - Median (IQR) 17.4 (11.8 27.0) 17.2 (11.8, 25.8) 17.3 (11.8, 25.8) 17.2 (11.9, 26.9) 17.2 (11.7, 26.7)
AIDS - % 0.1% 0.1% 0.1% 0.0% 0.0%
Malignancy - % 6.2% 11.5% 14.0% 16.7% 4.8%
CHF - % 2.6% 10.4% 13.9% 11.6% 1.0%
CPD - % 12.8% 17.0% 16.1% 17.4% 8.5%
Cerebrovascular disease - % 7.3% 13.5% 12.3% 11.2% 3.4%
Dementia - % 3.2% 6.7% 8.2% 7.0% 1.9%
Diabetes - % 10.3% 20.2% 18.7% 23.8% 6.0%
Hemiplegia. - % 1.3% 1.8% 1.4% 1.5% 0.5%
Hypertension - % 27.2% 39.% 39.3% 39.0% 15.5%
MI - % 3.0% 5.0% 6.0% 3.9% 0.7%
Solid tumour - % 2.0% 3.2% 4.8% 4.4% 0.9%
Liver disease - % 0.9% 1.8% 3.0% 6.1% 0.5%
PVD - % 2.1% 5.4% 6.2% 4.6% 1.0%
Peptic ulcer - % 0.6% 1.2% 1.7% 1.9% 0.4%
Renal disease - % 1.7% 11.2% 16.4% 22.3% 1.1%
Rheumatic disease - % 2.3% 3.9% 3.1% 4.1% 1.1%
CKD - no data 0% 0% 0% 0.7% 34.4%
no CKD 84.8% 61.9% 62.1% 68.2% 58.0%
CKD stage 3a 10.0% 19.1% 20.1% 15.0% 5.0%
CKD stage 3b 4.0% 13.1% 12.1% 10.2% 2.0%
CKD stage 4 1.0% 5.3% 5.5% 2.6% 0.5%
CKD stage 5 0.2% 0.5% 0.2% 3.4% 0.1%
Charlson ≤ 0 - % 58.0% 31.9% 25.8% 23.3% 74.5%
1-10 - % 25.9% 29.4% 30.5% 30.1% 17.4%
11 + =% 16.2% 38.8% 43.7% 46.6% 8.2%
Chronic pulmonary disease (CPD), chronic heart failure (CHF), myocardial infarction (MI), peripheral vascular disease (PVD), acquired immunodeficiency
syndrome (AIDS).
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Summary of main findings
The incidence of AKI in an adult population reported
here, 15,325 pmp/yr (10,534 pmp/yr with AKIN 1, 2,772
pmp/yr with AKIN 2 and 2,020 pmp/yr with AKIN3), is
significantly higher than previous estimates reported in
the literature, [20] and is likely to be closer to the real inci-
dence in the population. The reasons for the higher inci-
dence we report here are several. This is an unselectedin-hospital population; there is increased testing of
creatinine due to heightened awareness; the laboratory
service in East Kent comprehensively covers the catch-
ment population; in general because of the geography of
our catchment area all patients in the area are admitted to
one of our three hospital sites; our population is older in
comparison to the United Kingdom average; and finally,
use of the the La France methodology will also increase
the reported incidence.
Table 2 A summary of the length of stay for: all patients, those who died in hospital, and those who survived to
hospital discharge, split by AKI stage
Statistic No AKI AKIN 1 AKIN 2 AKIN 3 No AKI info
(n = 20,464) (n = 3,961) (n = 927) (n = 633) (n = 10,030)
All patients
Mean (SD) 4.5 (10.5) 9.7 (14.6) 12.3 (16.0) 14.9 (18.5) 2.3 (9.8)
Median (IQR) 2 (0, 5) 5 (1, 12) 7 (3, 15) 9 (4, 20) 1 (0, 2)
Died in hospital
Mean (SD) 11.1 (14.4) 11.8 (16.3) 10.0 (11.9) 10.3 (12.2) 13.5 (29.1)
Median (IQR) 6 (2, 14) 6 (2, 15) 6 (2, 14) 6 (2, 14) 5 (1, 15)
Survived to hospital discharge
Mean (SD) 4.4 (10.4) 9.5 (14.5) 13.0 (17.1) 17.2 (120.5) 2.1 (8.8)
Median (IQR) 1 (0, 5) 5 (1, 11) 8 (3, 15) 11 (5, 22) 1 (0, 2)
Length of stay is summarised as a continuous variable, and then additionally split into categories.
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that patients with AKI, even after correcting for age,
gender, co-morbidity, and CKD, have an increase in
morbidity and mortality both in the short and long term
in comparison to patients without AKI. These outcomes
also hold true for small changes in SCr (AKIN 1). In
comparison with patients with no AKI those with AKIN
1 had a 52% longer hospital stay, a 2.8-fold increased
risk of admission to ITU, a 39% longer ITU stay (in
those who went to ITU), and a 2.4-fold greater in-
hospital mortality. Furthermore, patients with AKIN 1
had twice the long term risk of death, a 33% higher
likelihood of an increase in care, and a 42% higher
risk of re-admission within 30 days. In those patients
with AKIN 3 (the subject of the NCEPOD report)
[27] hospital LOS doubled, there was a 22 times
higher risk of admission to ITU and ITU LOS was
also doubled, consistent with national data from the
Intensive Care National Audit and Research Centre
[28]. Acute RRT support was required in 13.1% of pa-
tients with AKIN 3. Hospital mortality was 26-fold
greater and in those surviving to leave hospital there
was a 5.5-fold increased risk of subsequent death. Pa-
tients with AKIN 3 had a 7% higher risk of requiring
an increase in care and had a 54% higher risk of re-
admission within 30 days than patients with no AKI.
Overall, 0.45% of patients with AKI and 3.40% ofTable 3 A summary of the survival estimates at 6-month inte
Variable No AKI AKIN
6 m survival (95% CI) 0.94 (0.94, 0.94) 0.77 (0
12 m survival (95% CI) 0.92 (0.92, 0.93) 0.70 (0
18 m survival (95% CI) 0.91 (0.91, 0.92) 0.65 (0
24 m survival (95% CI) 0.90 (0.89, 0.90) 0.59 (0
Note that the AKI groups are based on ‘upgraded’ AKI risk. If a patient experiences
be upgraded at that point to the higher group.patients with AKIN 3 subsequently required chronic
RRT.
As the time of entry into the cohort was the date of
admission for each patient there is the possibility of re-
verse causality, for example a patient who has a longer
length of stay may have a greater risk exposure to the
development of AKI. However in this cohort, of the
5521 admissions with AKI, 4064 (73.6%) already had
AKI on admission.
Strengths and weaknesses of study
The population-based analysis reported here considers
all patients admitted in a general hospital setting in the
United Kingdom during a 6 month period. The catch-
ment population for this cohort is from East Kent in the
South East Coast of England. Incomparison to the wider
population in England East Kent has an older population
(mean age 42 years compared to the national mean age
of 39) but with fewer ethnic minorities (6.3% of Black
and Ethnic minority compared with 14.6% nationally)
[21]. Nevertheless, we believe that data linkages between
the pathology, hospital data warehouse and renal sys-
tems have enabled us to come closer to the real inci-
dence and outcomes of AKI managed in-hospital than
any study published in the literature to date.
This study is a retrospective database study and clearly
has limitations. Key to the definition of AKI is knowledgervals along with corresponding confidence intervals
1 AKIN 2 AKIN 3
.75, 0.78) 0.48 (0.45, 0.52) 0.39 (0.35, 0.43)
.68, 0.71) 0.37 (0.34, 0.40) 0.28 (0.25, 0.31)
.63, 0.66) 0.32 (0.29, 0.35) 0.22 (0.19, 0.25)
.58, 0.61) 0.27 (0.24, 0.29) 0.18 (0.16, 0.20)




















Patient survival by AKI
Figure 2 Kaplan-Meier survival by stage of AKI. Note that the
AKI groups are based on ‘upgraded’ AKI risk.
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threshold value of SCr from which change is measured
(reference SCr). The importance of baseline SCr is in the
determination of pre-existing CKD and this value should
be based on SCr values available > 3 months prior to
the index event. The reference SCr should be ideally be
the lowest SCr recorded within 90 days of the event to
distinguish this value from the baseline SCr. However,
practically in many cases there may be either few or
no pre-hospitalisation SCr values making distinctionTable 4 Regression analyses examining the association betwe
LOS, ITU utilisation, increase in care and readmission
Risk of death In-hospital
mortality
ITU transfer






1 No AKI 1 1 1
AKIN 1 4.85 (4.51, 5.21) 4.29 (3.68, 5.01) 2.36 (1.90, 2.93
AKIN 2 12.0 (11.0, 13.1) 16.8 (13.5, 21.1) 4.72 (3.36, 6.61
AKIN 3 15.6 (14.2, 17.1) 24.7 (18.8, 32.3) 23.8 (16.4, 34.6
2 No AKI 1 1 1
AKIN 1 3.11 (2.89, 3.35) 2.98 (2.53, 3.52) 2.63 (2.11, 3.28
AKIN 2 7.54 (6.89, 8.25) 13.5 (10.5, 17.5) 5.43 (3.88, 7.61
AKIN 3 11.6 (10.6, 12.7) 25.2 (18.6, 34.5) 23.9 (16.6, 34.4
3 No AKI 1 1 1
AKIN 1 1.89 (1.74, 2.04) 2.41 (1.99, 2.91) 2.76 (2.20, 3.46
AKIN 2 3.81 (3.46, 4.18) 12.1 (8.84, 16.5) 6.03 (4.58, 8.51
AKIN 3 5.49 (4.97, 6.06) 26.3 (17.8, 38.8) 22.4 (15.5, 32.2
Model 1. Unadjusted. Model 2. Adjusted for age and gender. Model 3. Adjusted for
chronic kidney disease (CKD), admission from residential or nursing care, deprivatio
12 months. All values are statistically significant, with p values < 0.001. The outcom
spending any time in ITU during their hospital stay; Increase in Care - a patient bein
Hospital Re-admission – a patient being re-admitted to hospital within 30 days followi
the length of stay of a patient without AKI; Relative ITU Length of Stay – the ratio of IT
of stay in ITU of a patient without AKI.between baseline and reference SCr impossible. This is
an area that requires further guidance and consensus
from the international community and various strategies
have been suggested including varying the baseline/
reference creatinine from admission to 365 days prior
[22], taking the average of values between 7–365 days
prior to admission [29], back calculating reference SCr
for missing values from an assumed MDRD glomerular
filtration rate of 75 ml/min/1.73 m2 [30], and (most re-
cently) a method employing multiple imputation using
known comorbidity strengthened by factoring in the low-
est admission SCr [31]. For simplicity we chose to use the
lowest SCr in the 12 months prior to the acute rise to de-
fine AKI. It may be that by doing this we have included
patients with progressive CKD and defined them as AKIN
1. However, as Lafrance et al. demonstrated and our data
confirms, patients with AKIN 1 using this methodology
still have a significantly increased likelihood of a specific
adverse outcome occurring compared to patients with no
AKI [22].
The lowest serum creatinine in the 12 months follow-
ing discharge was utilised to categorise AKI (for those
without pre-hospitalisation creatinine) in 8.2% of admis-
sions with AKI. We acknowledge that the assumption
that AKI was present if serum creatinine improved fol-
lowing admission by greater than 26.4 μmol/L may not
always be correct but use of this methodology was only

















1 1 1 1
) 2.71 (2.17, 3.38) 1.93 (1.75, 2.13) 1.90 (1.84, 1.97) 1.38 (1.13, 1.68)
) 3.71 (2.56, 5.38) 2.25 (1.83, 2.76) 2.58 (2.43, 2.75) 1.54 (1.17, 2.01)
) 2.27 (1.36, 3.81) 2.09 (1.61, 2.72) 3.07 (2.85, 3.30) 2.25 (1.85, 2.73)
1 1 1 1
) 1.61 (1.29, 2.01) 1.69 (1.53, 1.87) 1.68 (1.62, 1.74) 1.43 (1.17, 1.74)
) 2.07 (1.43, 2.97) 2.00 (1.63, 2.46) 2.22 (2.09, 2.36) 1.56 (1.20, 2.04)
) 1.56 (0.93, 2.60) 1.94 (1.49, 2.53) 2.72 (2.53, 2.92) 2.27 (1.88, 2.76)
1 1 1 1
) 1.33 (1.06, 1.67) 1.42 (1.29, 1.57) 1.52 (1.47, 1.58) 1.39 (1.14, 1.69)
) 1.49 (1.02, 2.16) 1.50 (1.23, 1.83) 1.88 (1.77, 2.00) 1.42 (1.07, 1.87)
) 1.07 (0.64, 1.80) 1.54 (1.20, 1.99) 2.16 (2.01, 3.32) 2.18 (1.77, 2.68)
age, gender, primary diagnosis, modified Charlson co-morbidity score, stage of
n index, hospital admissions and outpatient appointments in the last
es are defined as follows: ITU transfer - a patient being transferred to and
g admitted from home and being discharged to residential or nursing care;
ng discharge; Relative Length of Stay – the ratio of length of stay in comparison to
U length of stay (in those patients who went to ITU) in comparison to the length
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baseline (9.9%) was less than in those where pre-admission
creatinine data was available (16.1%).
We cannot be certain that none of the patients with
insufficient SCr data experienced AKI. These patients
were significantly younger and had less co-morbidity
than those with sufficient SCr data and either had one
or no SCr result prior to, or following hospital admis-
sion. Survivors (9,830 of 10,030) were also short stay pa-
tients (LOS 0–2 days) and were therefore unlikely to
have sustained any degree of AKI. The 200 patients in
this group who did not survive the hospital admission
had a mean LOS of 13.5 days, lack of baseline SCr data
precluded derivation of AKI status in these patients.
This also raises the issue of possible ascertainment bias,
that sicker patients may have more creatinine tests, in-
creasing the probability of detecting AKI.
Co-morbidity data was extracted from the hospital
data warehouse using validated algorithms, however this
still relies on the accuracy of coding of clinical episodes
which may not necessarily be correct. This also applies
to the analysis of increase in care on discharge which re-
plies on the accurate coding on the PAS at time of
discharge.
While the statistical models used in this analysis have
accounted for multiple confounders identified in the lit-
erature to date there is always the possibility that there
may be other confounders hitherto unknown.
Finally, despite our estimates of the incidence of AKI in
a typical general hospital setting being the highest to date,
EKHUFT does not provide cardiothoracic, liver or burns
services and our reported incidence of AKI may still be an
under-estimation of the total population incidence.
Conclusions
This data comes closer to the real incidence and out-
comes of AKI managed in-hospital than any study pub-
lished in the literature to date. Nine percent of all
admissions and 15 percent of non-maternity and non-
day case admissions to hospital sustained an episode of
AKI with increased subsequent short and long term
morbidity and mortality, even in those with AKIN1.
What this study adds to existing knowledge is data enab-
ling a much more accurate assessment of the overall im-
pact of AKI on the healthcare economy. We provide
data concerning hospital and intensive care mortality,
LOS, readmission and RRT usage. We also detail the
rate of RRT after longer term follow up and the social
care impact in terms of increased level of care in those
surviving an episode of AKI. These increased adverse
outcomes from AKI confer an increased burden and cost
to the healthcare economy. The data we have presented
will enable this cost to be quantified and will furnish a
baseline for quality improvement projects aimed at earlyidentification, improved management, and where pos-
sible prevention, of AKI.
It has been suggested that milder forms of AKI defined
by creatinine criteria may simply represent a marker of
general system pathology and multi organ dysfunction,
not specifically related to kidney injury per se. Whether
this is true or not, AKI defines a group of patients whose
outcomes are poor, both in the short and long term,
who are sub-optimally managed, and who should repre-
sent a focus for patient safety improvement.
With the international agreement on the definition of
AKI and its validation in clinic research, it has become
clearer how important the effective management and
prevention of AKI is. Agreed definitions have provided a
comparable platform for the audit of AKI and its man-
agement and outcomes, both in hospital and in the
community.
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